von Bertrab R
Schweiz Med Wochenschr. 1985 Aug 6;115(31-32):1092-105.
In a 5-year retrospective study (1982-1978) in a well defined population of 332 patients (representing greater than or equal to 2140 anticoagulation years) from a heart specialist's practice, the question was studied whether optimum anticoagulation (Quick test between 18-29%, INR 4.0-2.75, Geigy thromboplastin, capillary blood method) with minimum complications could be achieved. In the qualitative study it was found that 75% of Quick determinations were in the optimum range for phenprocoumon, 71.6% for clorindion, 62% for acenocoumarol and 72% for all anticoagulants. 77% of phenprocoumon patients were optimally anticoagulated for more than 3 years. With phenprocoumon there was no difference in intensity of anticoagulation between the oldest and youngest patient groups, as all mean Quick values ranged over 20% (means Q% 1982-1978 = 25, INR = 3.0). It was also shown that after 6 months' anticoagulant therapy it is clearly recognizable whether optimum anticoagulation is feasible or not: at that moment the criteria for halting or continuing anticoagulant therapy can and should be reviewed.
在一项为期5年的回顾性研究(1982 - 1978年)中,对一位心脏病专家诊所中332名明确界定的患者群体(代表大于或等于2140个抗凝年)进行了研究,探讨是否能够实现具有最少并发症的最佳抗凝效果(奎克试验在18 - 29%之间,国际标准化比值在4.0 - 2.75之间,使用杰吉凝血活酶,毛细血管血法)。在定性研究中发现,75%的奎克测定结果处于苯丙香豆素的最佳范围内,氯茚二酮为71.6%,醋硝香豆素为62%,所有抗凝剂综合为72%。77%的苯丙香豆素患者在超过3年的时间里处于最佳抗凝状态。对于苯丙香豆素,最年长和最年轻患者组之间的抗凝强度没有差异,因为所有平均奎克值都超过20%(1982 - 1978年的平均Q% = 25,国际标准化比值 = 3.0)。研究还表明,在抗凝治疗6个月后,是否能够实现最佳抗凝效果是可以清晰识别的:此时可以而且应该重新审视停止或继续抗凝治疗的标准。